Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)

References

• Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer. Med Sci (Basel). 2020;8(1):15. doi: 10.3390/medsci8010015
   PubMedGoogle Scholar
• Koutros S, Decker KL, Baris D, et al. Bladder cancer risk associated with family history of cancer. Int J Cancer. 2021;148(12):2915–2923. doi: 10.1002/ijc.33486
   PubMed Web of Science ®Google Scholar
• Shore ND, Palou Redorta J, Robert G, et al. Non-muscle-invasive bladder cancer: an overview of potential new treatment options. Urol Oncol. 2021;39(10):642–663. doi: 10.1016/j.urolonc.2021.05.015
   PubMed Web of Science ®Google Scholar
• Reike MJ, Ingersoll MA, Müller DC, et al. Biology of BCG response in non-muscle invasive bladder cancer – 2021 IBCN updates part III. Urol Oncol. 2023;41(5):211–218. doi: 10.1016/j.urolonc.2022.09.012
   PubMed Web of Science ®Google Scholar
• Ślusarczyk A, Zapała P, Zapała Ł, et al. Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics. Int Urol Nephrol. 2019 Jul;51(7):1089–1099.
   PubMed Web of Science ®Google Scholar
• Zuiverloon TC, Nieuweboer AJ, Vékony H, et al. Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol. 2012;61(1):128–145. doi: 10.1016/j.eururo.2011.09.026
   PubMed Web of Science ®Google Scholar
• Lee M, Reilly M, Lindström LS, et al. Differences in survival for patients with familial and sporadic cancer. Int J Cancer. 2017;140(3):581–590. doi: 10.1002/ijc.30476
   PubMed Web of Science ®Google Scholar
• Egbers L, Grotenhuis AJ, Aben KK, et al. The prognostic value of family history among patients with urinary bladder cancer. Int J Cancer. 2015;136(5):1117–1124. doi: 10.1002/ijc.29062
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and Disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60–69. doi: 10.1016/j.eururo.2015.06.045
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA, et al. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24(4):344–348. doi: 10.1016/j.urolonc.2005.11.026
   PubMed Web of Science ®Google Scholar
• Hemminki K, Bermejo JL, Ji J, et al. Familial bladder cancer and the related genes. Curr Opin Urol. 2011;21(5):386–392. doi: 10.1097/MOU.0b013e32834958ff
   PubMed Web of Science ®Google Scholar
• Yu EY, Stern MC, Jiang X, et al. Family history and risk of bladder cancer: an analysis accounting for first- and second-degree relatives. Cancer Prev Res (Phila). 2022;15(5):319–326. doi: 10.1158/1940-6207.CAPR-21-0490
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology. 2006;49(3):466–477. discussion 475-7. doi: 10.1016/j.eururo.2005.12.031
   PubMed Web of Science ®Google Scholar
• Garg T, McMullen CK, Leo MC, et al. Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort. Cancer. 2021;127(4):520–527. doi: 10.1002/cncr.33300
   PubMed Web of Science ®Google Scholar
• Del Giudice F, Busetto GM, Gross MS, et al. Efficacy of three BCG strains (connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis. J Cancer Res Clin Oncol. 2021;147(10):3073–3080. doi: 10.1007/s00432-021-03571-0
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Brooks NA, Thomas LJ, et al. Bacillus calmette-guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer. Urol Oncol. 2017;35(5):201–207. doi: 10.1016/j.urolonc.2016.11.016
   PubMed Web of Science ®Google Scholar
• Aben KK, Baglietto L, Baffoe-Bonnie A, et al. Segregation analysis of urothelial cell carcinoma. Eur J Cancer. 2006;42(10):1428–1433. doi: 10.1016/j.ejca.2005.07.039
   PubMed Web of Science ®Google Scholar
• Mueller CM, Caporaso N, Greene MH. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol. 2008;26(5):451–64. doi: 10.1016/j.urolonc.2008.02.016
   PubMed Web of Science ®Google Scholar
• Siracusano S, Rizzetto R, Porcaro AB. Bladder cancer genomics. Urologia. 2020;87(2):49–56. doi: 10.1177/0391560319899011
   PubMed Web of Science ®Google Scholar
• Koutros S, Kiemeney LA, Pal Choudhury P, et al. Genome-wide association study of bladder cancer reveals new biological and translational insights. Eur Urol. 2023;84(1):127–137. doi: 10.1016/j.eururo.2023.04.020
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang T, Su W, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13(11):974. doi: 10.1038/s41419-022-05408-1
   PubMed Web of Science ®Google Scholar
• Zhang P, Kitchen-Smith I, Xiong L, et al. Germline and somatic genetic variants in the p53 pathway interact to affect cancer risk, progression, and drug response. Cancer Res. 2021;81(7):1667–1680. doi: 10.1158/0008-5472.CAN-20-0177
   PubMed Web of Science ®Google Scholar
• Ma F, Laster K, Dong Z. The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nat Commun. 2022;13(1):5651. doi: 10.1038/s41467-022-33351-4
   PubMed Web of Science ®Google Scholar
• van Rhijn BWG, Mertens LS, Mayr R, et al. FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 Treatment?†. Eur Urol. 2020;78(5):682–687. doi: 10.1016/j.eururo.2020.07.002
   PubMed Web of Science ®Google Scholar
• Velmahos CS, Badgeley M, Lo YC. Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images. Cancer Med. 2021;10(14):4805–4813. doi: 10.1002/cam4.4044
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Choi W. Molecular subtypes of bladder cancer. Curr Oncol Rep. 2018;20(10):77. doi: 10.1007/s11912-018-0727-5
   PubMed Web of Science ®Google Scholar
• Patel N, Miller DJ, Snavely AC, et al. A comparison of smoking history in the electronic health record with self-report. Am J Prev Med. 2020;58(4):591–595. doi: 10.1016/j.amepre.2019.10.020
   PubMed Web of Science ®Google Scholar
• Volk RJ, Mendoza TR, Hoover DS, et al. Reliability of self-reported smoking history and its implications for lung cancer screening. Prev Med Rep. 2020;17:101037. doi: 10.1016/j.pmedr.2019.101037
   PubMedGoogle Scholar
• Bijlsma N, Cohen MM. Expert clinician’s perspectives on environmental medicine and toxicant assessment in clinical practice. Environ Health Prev Med. 2018;23(1):19. doi: 10.1186/s12199-018-0709-0
   PubMed Web of Science ®Google Scholar
• Lipunova N, Wesselius A, Cheng KK, et al. Systematic review: genetic associations for prognostic factors of urinary bladder cancer. Biomark Cancer. 2019;11:1179299X19897255. doi: 10.1177/1179299X19897255
   PubMedGoogle Scholar
• Wallerand H, Bakkar AA, de Medina SG, et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis. 2005;26(1):177–184. doi: 10.1093/carcin/bgh275
   PubMed Web of Science ®Google Scholar
• Rink M, Xylinas E, Babjuk M, et al. Smoking reduces the efficacy of intravesical bacillus calmette-guérin immunotherapy in non-muscle-invasive bladder cancer. Eur Urol. 2012;62(6):1204–1206. doi: 10.1016/j.eururo.2012.08.057
   PubMed Web of Science ®Google Scholar
• Marsit CJ, Karagas MR, Danaee H, et al. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis. 2006;27(1):112–116. doi: 10.1093/carcin/bgi172
   PubMed Web of Science ®Google Scholar
• Woodruff RC, Thompson JN. The role of somatic and germline mutations in aging and a mutation interaction model of aging. J Anti Aging Med. 2003 Spring;6(1):29–39. doi: 10.1089/109454503765361560
   PubMedGoogle Scholar
• Vlachostergios PJ, Faltas BM, Carlo MI, et al. The emerging landscape of germline variants in urothelial carcinoma: implications for genetic testing. Cancer Treat Res Commun. 2020;23:100165. doi: 10.1016/j.ctarc.2020.100165
   PubMedGoogle Scholar
• Jackson L, Weedon MN, Green HD, et al. Influence of family history on penetrance of hereditary cancers in a population setting. EClinicalMedicine. 2023;64:102159. doi: 10.1016/j.eclinm.2023.102159
   PubMedGoogle Scholar
• Kingdom R, Wright CF. Incomplete penetrance and variable expressivity: from clinical studies to population cohorts. Front Genet. 2022;13:920390. doi: 10.3389/fgene.2022.920390
   PubMed Web of Science ®Google Scholar
• Storey JD, Madeoy J, Strout JL, et al. Gene-expression variation within and among human populations [published correction appears in. Am J Hum Genet. 2007;80(6):502–509.
   PubMed Web of Science ®Google Scholar
• Shepherd AR, Shepherd E, Nicholas RB. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Cochrane Database Syst Rev. 2017;3(3):CD012112. doi: 10.1002/14651858.CD012112.pub2
   PubMedGoogle Scholar